Myxobacteria ：Natural Pharmaceutical Factories

doi:10.13560/j.cnki.biotech.bull.1985.2014.12.007

Abstract

Abstract: In recent years, drug development of myxobacteria and its resistant metabolic products has become one of the hot topics of researches study. Myxobacteria is an kind of important natural products producer. There is rich diversity in both the chemical structure and biological activity of these secondary metabolites. The diversity and broad-spectrum activity of metabolites have great potential in drug development field. This review describes the unique cell behavior in myxobacteria and its outstanding ability of producing secondary metabolites, and also expounds the progress of epothilone drug development. Finally, we discuss the potential of developing myxobacterial secondary metabolites into new drugs.

Key words: Myxobacteria, Secondary metabolites, Epothiones, Drug discovery

Zhao Tingfeng, Gong Guoli. Myxobacteria ：Natural Pharmaceutical Factories[J]. Biotechnology Bulletin, 2014, 0(12): 40-46.

References

[1] Davies J, Ryan KS. Introducing the parvome: bioactive compounds in the microbial world[J]. ACS Chem Biol, 2012, 7(2)：252-259.
[2] Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery[J]. Eur J Med Chem, 2011, 46(10)：4769-4807.
[3] Newman DJ, Cragg GM. Natural products as sources of new drugs over 147 the 30 years from 1981 to 2010[J]. J Nat Prod, 2012, 75 (3)：311-335.
[4] Gerth K, Pradella S, Perlova O, et al. Myxobacteria: proficient producers of novel natural products with various biological activities -past and future biotechnological aspects with the focus on the genus Sorangium[J]. J. Biotechnol, 2003(106)：233-253.
[5] Bode HB, Muller R. Analysis of myxobacterial secondary metabolism goes molecular[J]. J Ind Microbiol Biotechnol, 2006, 33(7)： 577-588.
[6] Weissman KJ, Muller R. Myxobacterial secondary metabolites: bioactivities and modes-of-action[J]. Nat Prod Rep, 2010, 27(9)： 1276-1295.
[7] Gentzsch J, Hinkelmann B, Kaderali L, et al. Hepatitis C virus complete life cycle screen for identification of small molecules with pro-or antiviral activity[J]. Antiviral Res, 2011, 89(2)：136-148.
[8] Nickeleit I, Zender S, Sasse F, et al. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1)in mediating antitumor activities in response to proteasome inhibition[J]. Cancer Cell, 2008, 14(1)：23-35.
[9] Juana Diez1, Javier PM, Jordi M, et al. Myxobacteria: natural pharmaceutical factories[J]. Microbial Cell Factories, 2012, 11 (52)：1-3.
[10] Reichenbach H. Myxobacteria, producers of novel bioactive substances[J]. J Ind Microbiol Biotechnol, 2001, 27(3)：149-156.
[11] Velicer GJ, Vos M. Sociobiology of the myxobacteria[J]. Annu Rev Microbiol, 2009(6)：599-623.
[12] Kaiser D. Coupling cell movement to multicellular development in myxobacteria[J]. Nat Rev, 2003, 1(1)：45-54.
[13] Nan B, Chen J, Neu JC, et al. Myxobacteria gliding motility requires cytoskeleton rotation powered by proton motive force[J]. Proc Natl Acad Sci USA, 2011, 108(6)：2498-2503.
[14] Xiao Y, Wei X, Ebright R, et al. Antibiotic production by myxobacteria plays a role in predation[J]. J Bacteriol, 2011, 193 (18)：4626-4633.
[15] Berleman JE, Kirby JR. Deciphering the hunting strategy of a bacterial wolfpack[J]. FEMS Microbiol Rev, 2009, 33(5)： 942-957.
[16] Schneiker S, Perlova O, Kaiser O, et al. Complete genome sequence of the myxobacterium Sorangium cellulosum[J]. Nat Biotechnol, 2007, 25(11)：1281-1289.
[17] Bon RS, Waldmann H. Bioactivity-guided navigation of chemical space[J]. Acc Chem Res, 2010, 43(8)：1103-1114.
[18] Weissman KJ, Muller R. A brief tour of myxobacterial secondary metabolism[J]. Bioorg Med Chem, 2009, 17(6)：2121-2136.
[19] Rix U, Fischer C, Remsing LL, et al. Modification of post-PKS tailoring steps through combinatorial biosynthesis[J]. Nat Prod Rep, 2002, 19(5)：542-580.
[20] Davies J, Spiegelman GB, Yim G. The world of subinhibitory antibiotic concentrations[J]. Curr Opin Microbiol, 2006, 9(5)： 445-453.
[21] Bode HB, Muller R. The impact of bacterial genomics on natural product research[J]. Angew Chem Int Ed, 2005, 44(42)： 6828-6846.
[22] Bentley SD, Chater KF, Cerdeno-Tarraga AM, et al. Complete
[33] Lee FYF, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor activity[J]. Clin Cancer Res, genome sequence of the model actinomycete Streptomyces 2001(, 7)：1429-1437. coelicolor[J]. Nature, 2002, 417(6885)：141-147.
[23] Ikeda H, Ishikawa J, Hanamoto A, et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomy-ces avermitilis[J]. Nat Biotechnol, 2003, 21(5)：526-531.
[24] Giannakakou P, Gussio R, Nogales E, et al. A common pharmacop-hore for epothilone and taxanes: molecular basis for drug resistan-ce conferred by tubulin mutations in human cancer cells[J]. Proc Natl Acad Sci USA, 2000(97)：2904-2909.
[25] Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha-, beta-tubulin by electron crystallography[J]. Science, 2004(5)：866-869.
[26] Verrills NM, Flemming CL, Liu M, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interaction[J]. Chem Biol, 2003(10)：597-607.
[27] Chou TC, O’Connor OA, Tong WP, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumour xenografts in nude mice[J]. Proc Natl Acad Sci USA, 2001(98)：8113-8118.
[28] Bode CJ, Gupta ML, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules[J]. Biochemistry, 2002(41)：3870-3874.
[29] Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone[J]. Cancer Chemother Pharmacol, 2009,(63)：201-212 [30] Mekhail T, Chung C, Holden S, et al. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days[J]. Proc Am Soc Clin Oncol, 2003(22)：129(abstract 515).
[31] Sessa C, Perotti A, Malossi A, et al. Phase I and pharmacokinetic (PK)study of the novel epothilone BMS-310705 in patients(pts) with advanced solid cancer[J]. Proc Am Soc Clin Oncol, 2003(2)：130(abstract 519).
[32] Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones[J]. Curr Med Chem Anticancer Agents, 2002(2)： 123-148.
[34] Sessa C, Perotti A, Lladò A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule[J]. Ann Oncol, 2007(18)：1548-1553.
[35] Nicolaou KC, Winssinger N, Pastor J, et al. Synthesis of epothilones A and B in solid and solution phase[J]. Nature, 1997(387)： 268-272.
[36] Nicolaou K, Roschangar F, Vourloumis D. Chemistry and biology of epothilone[J]. Angew Chem, 1998(110)：2120-2153.
[37] Nicolaou KC, King NP, Finlay MR, et al. Total synthesis of epothilone E and related side chain modified analogs via a Stille coupling based strategy[J]. Bioorg Med Chem, 1999, 7: 665-697.
[38] Su DS, Horwitz SB, et al. Total synthesis of(3)-epothilone B: an extension of the Suzuki coupling method and insights into structure activity relationships of the epothilones[J]. Angew Chem Int Ed Engl, 1999, 36: 757-759.
[39] Yang Z, He Y, Vourloumis D, et al. Total synthesis of epothilone A： the ole ￠ n metathesis approach[J]. Angew Chem Int Ed Engl, 1997, 36: 166-168.
[40] Sawada D, Shibasaki M. Enantioselective total synthesis of epothilone A using multifunctional asymmetric catalyses[J]. Angew Chem Int Ed, 2000, 39: 209-213.
[41] Nicolaou KC, He Y, Roschangar F, et al. Total synthesis of epothilone E and analogues with modified side chains through the Stille coupling reaction[J]. Angew Chem Int Ed Engl, 1998, 37: 84-87. [42] Gerth K, Bedorf N, H?fle G, et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria)-production, physico-chemical and biological properties[J]. J Antibiot, 1996, 49: 560-564.
[43] Gerth K, Steinrich H, Hofle G, et al. Studies on the biosynthesis of epothilones: the biosynthetic origin of the carbon skeleton[J]. J Antibiotics, 2000, 53: 1373-1377.
[44] Tang L, Shah S, Chung L, et al. Cloning and heterologous expression of the epothilone gene cluster[J]. Science, 2000(287)：640-642.
[45] Julien B, Shah S. Heterogonous expression of epothilone biosynthetic genes in Myxococcus xanthus[J]. Antimicrob Agents Chemother, 2002, 46: 2772-2778.
[46] Lau J, Frykman S, Regentin R, et al. Optimizing the heterologous production of Epothilone D in Myxococcus xanthus[J]. Biotechnol Bioeng, 2002, 78: 280-288.
[47] Arslanian RL, Tang L, Blough S, et al. A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus[J]. J Nat Prod, 2002, 65: 1061-1064.
[48] Gerth K, Washausen P, H?fle G, et al. The jerangolids: A family of new antifungal compounds from Sorangium cellulosum (myxobacteria). production, physico-chemical and biological properties of jerangolid A[J]. J Antibiot, 1996, 49: 71-75.
[49] Mahmud T, Bode HB, Silakowski B, et al. A novel biosynthetic pathway providing precursors for fatty acid biosynthesis and secondary metabolite formation in myxobacteria[J]. J Biol Chem,
[55] 龚国利 , 陈松 , 李慧 , 等 . 基因组重组技术选育埃博霉素 B 高产菌株[J]. 中国抗生素杂志 , 2013, 38(2)：106-110.
[56] 龚国利 , 陈松 , 李慧 , 曾桥 . 改良 Genome shuffling 技术选育埃博霉素 B 高产菌株[J]. 中国酿造 , 2012, 31(11)：42-45.
[57] Gong GL, Jia L, Li H.Preparation and adsorption properties of mixed-templates molecularly imprinted polymers of epothilone B[J]. J ChemPharm Res, 2014, 6(3)：1421-1427.
[58] 龚国利 , 陈松 , 李慧 . 一种埃博霉素 B 的发酵生产工艺：中国 , ZL 201110346091.0[P] . 2012-3-14.
[59] 龚国利 , 王娜 , 刘丽丽．响应面法优化纤维堆囊菌 SoF5-76 产埃博霉素 B 发酵培养基[J]．生物技术通报 , 2014(1)： 171-176.
[60] 龚国利 , 贾琳 , 黄菲菲 , 许重要 . 微生物合成抗癌药物埃博霉素的研究进展[J]. 中国新药杂志 , 2009, 18(16)：1515-1520.
[61] 龚国利 , 刘丽丽 . 多孔陶瓷吸附固定纤维堆囊菌发酵制备埃博 2002(, 277), 23768-32774. 霉素[J]. 中国生物工程杂志 , 2014, 34(3)：109-114.
[50] Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action[J]. Cancer Res, 1995, 55: 2325-2333.
[51] Wang JD, Zhang H, Ying LP, et al. Five new epothilone metabolites from Sorangium cellulosum strain So0157-2[J]. The Journal of Antibiotics, 2009(62)：483-487.
[52] 龚国利 . 黏细菌的 Genome shuffling 育种技术及其抗癌药物埃博霉素的高产改造[D] . 济南: 山东大学 , 2007.
[53] Gong GL, Sun X, Liu XL, et al. Mutation of Sorangium cellulosum and a high-throughput screening method for improving the production of Epothilones[J]. J Ind Microbio Biot, 2007, 34: 615-623.
[54] 龚国利 , 孙欣 , 刘新利 , 李越中 . Genome shuffling 提高黏细菌产生埃博霉素的能力[C] , 中国微生物学会全国会员代表大会及学术年会论文摘要集 , 2006: 78.
[62] 龚国利 , 刘丽丽 , 王娜 , 用于吸附固定纤维堆囊菌的硅藻土基多孔陶瓷制备[J]. 现代化工 , 2013, 33(11)：66-70.
[63] Hong J. Role of natural product diversity in chemical biology[J]. Curr Opin Chem Biol, 2011, 15(3)：350-354.
[64] Scheller N, Mina LB, Galao RP, et al. Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates[J]. Proc Natl Acad Sci USA, 2009, 106 (32)：13517-13522.
[65] Noueiry AO, Diez J, Falk SP, et al. Yeast Lsm1p-7p/Pat1p deadenylation-dependent mRNA-decapping factors are required for brome mosaic virus genomic RNA translation[J]. Mol Cell Biol, 2003, 23(12)：4094-4106.